NCT00104455

Dose Response to Recombinant Factor VIIa When Administered for Bleed

Recombinant Activated Factor VII (rFVIIa/NovoSeven) Dose Response Trial in Healthy Volunteers: A Double-Blind, Placebo-Controlled, Cross-over, Dose-Escalation Trial to Investigate the Dose Response to REcombinant Factor VIIa When Administered for Bleeding Following Punch Biopsies in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 64 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: Male
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

This trial is conducted in the United States of America (USA). The purpose of this trial is to investigate the dose response to recombinant factor VIIa in healthy volunteers when administered for bleed.

Conditions

• Congenital Bleeding Disorder
• Healthy

Interventions

Type	Name	Description
DRUG	activated recombinant human factor VII

Timeline

• Start date: 2004-06-01
• Primary completion: 2004-11-01
• Completion: 2004-11-01
• First posted: 2005-03-01
• Last updated: 2017-01-12

Locations

1 site across 1 country: United States